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Intraductal oncocytic papillary neoplasm of the pancreas: a
radio-pathological case study
Abstract
CONTEXT: An intraductal oncocytic papillary neoplasm is a rare pancreatic tumor with the potential of
developing invasive carcinoma. Its differentiation from other cystic-like neoplasms of the pancreas, such
as intraductal papillary mucinous neoplasms, is a challenge for pancreatic imaging. CASE REPORT:
We present the case of a 76-year-old male with painless jaundice caused by an intraductal oncocytic
papillary neoplasm of the pancreas. The imaging findings on computed tomography, magnetic
resonance including diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission
tomography are presented and the radio-pathological correlations are discussed. CONCLUSION: An
intraductal oncocytic papillary neoplasm of the pancreas appears as a cystic tumor communicating with
the dilated pancreatic duct featuring intraductal tumor nodules. Intraductal oncocytic papillary
neoplasms show a high (18)F-fluorodeoxyglucose-uptake in positron emission tomography and low
diffusion values in diffusion-weighted imaging including apparent diffusion coefficient maps which
may be a valuable attribute in distinguishing these rare lesions from intraductal papillary mucinous
neoplasms.
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ABSTRACT 
Context An intraductal oncocytic papillary neoplasm is a rare pancreatic tumor with the potential of developing invasive carcinoma. 
Its differentiation from other cystic-like neoplasms of the pancreas, such as intraductal papillary mucinous neoplasms, is a challenge 
for pancreatic imaging. Case report We present the case of a 76-year-old male with painless jaundice caused by an intraductal 
oncocytic papillary neoplasm of the pancreas. The imaging findings on computed tomography, magnetic resonance including 
diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography are presented and the radio-pathological 
correlations are discussed. Conclusion An intraductal oncocytic papillary neoplasm of the pancreas appears as a cystic tumor 
communicating with the dilated pancreatic duct featuring intraductal tumor nodules. Intraductal oncocytic papillary neoplasms show 
a high 18F-fluorodeoxyglucose-uptake in positron emission tomography and low diffusion values in diffusion-weighted imaging 
including apparent diffusion coefficient maps which may be a valuable attribute in distinguishing these rare lesions from intraductal 
papillary mucinous neoplasms. 
 
INTRODUCTION 
 
An intraductal oncocytic papillary neoplasm is a rare 
pancreatic tumor which was first described by Adsay et 
al. in 1996 [1]. Until now, only a few case reports and 
small series have been reported in the literature [1, 2, 3, 
4, 5, 6, 7, 8, 9, 10]. An intraductal oncocytic papillary 
neoplasm is a distinct entity, having the potential of 
developing invasive carcinoma, and must be 
differentiated from other cystic-like neoplasms of the 
pancreas, such as intraductal papillary mucinous 
neoplasms (IPMNs) [2]. Both intraductal oncocytic 
papillary neoplasms and IPMNs appear cystic because 
they cause ductal dilation due to the intraductal 
proliferation of mucinous cells [4]. The formation of 
the tumor cells of intraductal oncocytic papillary 
neoplasm (such as oncocytic cells and the complex 
morphology of the papillae) distinguishes them from 
the more common IPMN [1]. However, the clinical and 
pathological details of intraductal oncocytic papillary 
neoplasms remain unclear and are still under debate 
[5]; some authors have argued that intraductal 
oncocytic papillary neoplasms are a subgroup of 
IPMNs [1]. However, the latest classification separates 
both entities [11]. 
We performed computed tomography (CT) and 
magnetic resonance imaging (MRI) as well as 
diffusion-weighted imaging and 18F-fluorodeoxy-
glucose positron emission tomography (FDG-PET) on 
a patient with an intraductal oncocytic papillary 
neoplasm. The images obtained and the radio-
pathological correlations are discussed. 
 
CASE REPORT 
 
A 76-year-old male underwent ultrasonography of the 
abdomen due to painless jaundice. A cystic tumor in 
the pancreatic head was discovered and the patient was 
admitted to our hospital for further evaluation and 
treatment. Physical examination revealed scleral icterus 
but was otherwise normal. He suffered from pre-
existing arterial hypertension and actinic keratodermia 
of the vertex. Routine laboratory tests on admission 
showed elevated serum concentrations of the liver and 
pancreatic enzymes (AST 215 U/L, reference range 10-
50 U/L; ALT 288 U/L, reference range 10-50 U/L; 
GGT 860 U/L, reference range 8-61 U/L; alkaline 
phosphatase 599 U/L, reference range 40-129 U/L; 
pancreatic amylase 130 U/L, reference range 13-53  
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U/L) as well as elevated serum bilirubin levels (232 
µmol/L, reference level: 0-21 µmol/L). The tumor 
marker, CA 19-9, was within normal limits. 
 
Imaging Findings 
 
CT (Somatom Definition, Siemens Medical Solutions, 
Forchheim, Germany) confirmed the cystic lesion in 
the pancreatic head and revealed another cystic lesion 
in the pancreatic tail. Both lesions contained several 
septae and solid elements which showed uptake of 
iodine-containing contrast media (Figure 1). The main 
pancreatic duct was dilated in the pancreatic head, 
body, and tail. Furthermore, dilatation of the common 
bile duct as well as of the intrahepatic bile ducts was 
found. 
MRI (Signa EchoSpeed EXCITE HD, 1.5 Tesla, GE 
Healthcare, Waukesha, WI, U.S.A.) was performed and 
showed two mainly cystic tumors in the pancreatic 
head and tail with low intensity in T1-weighted images 
and high intensity in T2-weighted images. The 
intracystic solid tumor nodules were T1 and T2 
hypointense and showed an intensive early, focal 
gadolinium uptake on dynamic contrast-enhanced T1-
weighted images (Figure 2ab). T1-weighted contrast-
enhanced images, T2-weighted images, and magnetic 
resonance cholangiopancreatography (MRCP) clearly 
depicted the communication between the two separate 
tumors and the pancreatic duct (Figure 2c). 
Diffusion-weighted imaging was performed using a 
diffusion-weighted single-shot echo-planar-imaging 
sequence with short tau inversion recovery-based fat-
suppression. This diffusion-weighted imaging sequence 
was performed under breath-hold during inspiration. 
Water diffusion was measured at b-values of 0, 150, 
500, and 1,000 s/mm2. Diffusion-weighted imaging 
visualized the solid tumor parts, the pancreatic duct and 
the distal common bile duct as well as the cystic parts 
in the pancreatic head and tail with different intensities 
up to the b-value used. The signal intensities of all the 
cystic tumor parts were the highest on diffusion-
weighted imaging with lower b-factors. At a higher b-
factor (b=500 s/mm2), the signal intensities of the cysts 
decreased considerably, suggesting a T2 shine-through 
effect. Apparent diffusion coefficient maps confirmed 
these findings with high values (0.97x10-3 mm2/s) for 
all the cystic lesions and low values (0.57x10-3 mm2/s) 
for the solid tumor parts within the cysts as well as in 
the pancreatic duct (0.62x10-3 mm2/s) (Figure 3). 
Figure 1. Curved coronal CT image of the pancreas in the portal
venous phase of contrast enhancement. Communication of the
mainly cystic intraductal oncocytic papillary neoplasm to the main
pancreatic duct in the pancreatic head (arrowhead) and tail is clearly
depicted (arrows). Please note the considerable size of the solid 
tumor part in the tail of the pancreas (asterisk). 
Figure 2. a. Axial T2-weighted image at the level of the pancreas 
shows the manifestation of the intraductal oncocytic papillary 
neoplasm in the pancreatic tail. Communication to the pancreatic 
duct can be identified (arrowhead) as well as the hypointense solid 
tumor parts (arrows). b. Axial T1-weighted image after contrast
enhancement with gadolinium at the same level also shows 
communication to the pancreatic duct and strong enhancement of the 
solid tumor parts (arrows). c. MRCP clearly depicts communication 
of the dilated pancreatic duct (pd) with the intraductal oncocytic 
papillary neoplasm in the pancreatic head (asterisk) and tail 
(arrowhead); the solid tumor components are observable. (bd: dilated 
common bile duct). 
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FDG-PET acquired on a combined PET-CT in-line 
system (Discovery VCT; GE HealthCare, Waukesha, 
WI, U.S.A.) showed an increased uptake by the 
intracystic solid tumor parts in the pancreatic head 
(standard uptake value, SUV: 15.4) and tail (SUV: 
17.8), consistent with high metabolic activity (Figure 
4). 
 
Surgical Findings 
 
Due to the multilocular spread of the pancreatic tumor, 
a total splenopancreatectomy with partial resection of 
the stomach, duodenum and omentum was considered 
necessary; this was successfully performed after 
diagnostic laparoscopy which ruled out peritoneal 
implants. The tumor was well encapsulated without 
signs of vascular infiltration. Interestingly, the common 
bile duct had to be resected several times due to intra-
ductal papillary proliferations in the fresh frozen 
sections. The reconstruction included an end-to-side 
hepatojejunostomy as well as an end-to-side 
gastrojejunostomy with Braun’s anastomosis. The 
patient was discharged for further rehabilitation after 
an uneventful postoperative course of 15 days. 
 
Pathological Findings 
 
The surgical specimen contained a 10 cm multilocular 
cystic mass with several papillary projections in the tail 
of the pancreas and a 6 cm solid area in the head of the 
Figure 4 a. Original attenuation-corrected coronal PET image 
demonstrates high uptake in the pancreatic head (arrowhead) and tail 
(arrow). b. c. Original attenuation-corrected axial PET image at the 
level of the pancreas shows high uptake in the pancreatic tail (arrow). 
Corresponding fused FDG-PET/CT at the same level. 
Figure 3. Diffusion weighted images at b=0, 150 and 500 s/mm2 and 
apparent diffusion coefficient-mapping generated from b-values at 
b=150 s/mm2. a. b. c. Axial diffusion-weighted images displayed
with an inverted grey-scale at the level of the pancreatic tail acquired
at b=0, 150 and 500 s/mm2. The diffusion-weighted imaging
sequences allowed the visualization of the solid tumor parts
(asterisk), the pancreatic duct (arrow), the distal common bile duct
(arrowhead) as well as the cystic parts in the pancreatic tail (double
arrow) with different intensity. Signal intensities of all the cystic 
tumor parts were highest on diffusion-weighted imaging with b-
values at 0 and 150 s/mm2; with a higher b-value of 500 s/mm2, 
signal intensities of the cysts decreased significantly indicating a T2
shine through effect. d. Apparent diffusion coefficient-maps 
confirmed the T2 shine-through effect for all cystic lesions (colored
red; double arrow) but not for the solid tumor parts within the cystic
components and the pancreatic duct (colored blue; asterisk and
arrow). Intraductal oncocytic papillary neoplasm in the common bile
duct, confirmed pathologically, was not identifiable on apparent 
diffusion coefficient-mapping (arrowhead). 
Figure 5. a. Surgical specimen composed of partial gastrectomy, 
duodenum, pancreas, spleen, and partial omentum. The pancreas is 
enlarged and shows nodular formations, mainly located in the tail 
(arrows). (asterisk: ductus choledochus). b. Cut surface of the 
pancreas, revealing a solid area in the head of the pancreas and a 
multilocular lesion in the tail of the pancreas with solid and cystic 
parts which contain slightly thick mucin and soft grey-brown luminal 
papillary masses (arrow). One of these papillary masses is also 
present in the ductus choledochus (arrowhead), close to the surgical 
resection margin (asterisk). Ductus choledochus and main pancreatic 
duct appear dilated. 
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pancreas which caused dilatation of the main 
pancreatic duct (Figure 5). Microscopic features of the 
pancreatic tumor showed a particularly complex 
architecture with arborizing papillae as well as invasive 
areas characterized by small nests of cells with 
extracellular mucin accumulation. The tumor cells in 
both components showed abundant granular 
eosinophilic cytoplasm, a characteristic feature of this 
neoplasm due to numerous mitochondria (Figure 6). 
The neoplastic cells expressed abundant and diffuse 
hepatocyte paraffin-1 and cytokeratin 19 whereas the 
expression of CEA, MUC1, MUC2 and synaptophysin 
was focal. No expression of CDX2 or chromogranin 
was observed. 
Of the 21 regional lymph nodes examined, we found a 
metastatic process in only two of them. 
 
DISCUSSION 
 
Up to now, to the best of our knowledge, only 20 cases 
of patients having an intraductal oncocytic papillary 
neoplasm of the pancreas have been reported in the 
literature [1, 2, 3, 4, 5, 6, 7, 8, 9, 10] and only seven of 
them involved MRI and CT imaging [2, 3, 4, 5, 6, 7, 8]. 
All these cases showed almost similar imaging findings 
describing a cystic tumor with dilatation of the 
pancreatic duct and nodule-like intraductal tumor parts 
with uptake of iodine or gadolinium-containing 
contrast media. Four cases, like ours, showed 
multilocular tumor involvement [2, 4, 6, 7] whereas the 
other cases were monolocular [3, 8]. Three cases had 
metastatic involvement of the liver [1, 7, 10] and one 
case had regional lymph node metastases [3]. These 
findings are consistent with the images obtained in our 
case where no distant metastases were present but there 
was regional lymph node involvement which was 
solely detected pathologically and not by CT, MRI, 
diffusion-weighted imaging or FDG-PET. In all cases 
reported, a preoperative differentiation of intraductal 
oncocytic papillary neoplasms from IPMNs could not 
be made using MRI and CT. Except for one case, 
where the intraductal oncocytic papillary neoplasm 
showed no communication with the main pancreatic 
duct and, therefore, mimicked a mucinous cystic 
neoplasm [5], communication with the main pancreatic 
duct was the leading feature for the assumed diagnosis 
of an IPMN. MRCP is still the best non-invasive 
imaging modality for IPMNs, being superior to 
endoscopic retrograde cholangiopancreatography 
(ERCP) in the detection of cystic dilatation of the 
pancreatic ducts, number of nodules or septa in the 
dilated branch duct, as well as demonstrating 
communication of cystic tumors with the main 
pancreatic duct [12]. In our case, MRI and MRCP 
clearly depicted the communication of the intraductal 
oncocytic papillary neoplasm to the main pancreatic 
duct. We were also able to detect nodule-like 
intraductal tumor parts on MRCP and its source 
images. 
FDG-PET has proved to be useful for detecting 
malignant tumors of the pancreas, distant metastases in 
suspected pancreatic cancer, and parenchymal invasion 
of IPMN [13, 14]. Sperti et al. recently reported that 
18F-FDG PET was more accurate than MRI and CT in 
distinguishing benign from malignant IPMNs [15]. 
Experience with intraductal oncocytic papillary 
neoplasm is limited, with only two case reports until 
now [4, 8]. Both cases showed strong FDG-uptake of 
the tumor nodules within the cystic components, with 
standard uptake values (SUVs) comparable to our case. 
Generally, benign tumors show significantly lower 
SUVs as compared to malignant tumors indicating a 
lower glucose-metabolism, which correlates with the 
diminished biological activity. The SUVs in the present 
case were very high. One reasonable explanation might 
be that intraductal oncocytic papillary neoplasms have 
high replication rates and therefore a higher glucose-
metabolism. Oncocytomas have generally been proven 
to be notably active metabolically. As a matter of fact, 
several cases of non-pancreatic oncocytoma including 
those in the thyroid, pararenal, submandibular, and 
parotid glands showed intense activity on 18F-FDG-
PET [16, 17, 18, 19]. In our case, the intraductal 
oncocytic papillary neoplasm was not solely 
intraepithelial since histological evaluation revealed 
multilocular transformation to invasive carcinoma 
which may have also caused high SUVs. However, in 
both published cases involving FDG-PET and 
intraductal oncocytic papillary neoplasms, there was no 
evidence of tumor invasion but there was still notable 
metabolic activity [4, 8]. 
Diffusion-weighted imaging has proven to be feasible 
for tumor and metastasis detection in a whole-body 
setting [20]. Diffusion-weighted imaging was shown to 
be useful in the detection and characterization of 
malignant hepatic lesions [21] and pancreatic cancer 
[22]. Whereas small b-values (b=20-50 s/mm2) are 
considered to give the best results in tumor detection of 
the liver [21], in pancreatic tumor imaging higher b-
Figure 6. Microscopic features of the pancreatic tumor showing a
particularly complex architecture with arborizing papillae as well as
invasive areas characterized by small nests of cells with extracellular
mucin accumulation. Invasion front composed of tumor cells with
abundant eosinophilic cytoplasm surrounded by abundant mucin. A
perineural invasion in the tumor area can also be observed as can a
peritumoral desmoplastic stromal reaction. 
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values (b=1,000 s/mm2) have added diagnostic value 
[23]. 
In the present case, diffusion-weighted imaging with 
low and medium b-values (b=150, 500 s/mm2) allowed 
a clear depiction and differentiation of the solid and 
cystic tumor parts as compared to the regular 
pancreatic tissue. The solid tumor parts mostly 
represent the papillary component of the intraductal 
oncocytic papillary neoplasm which was also 
detectable by MRI and CT. This correlated very well 
with the macropathologic specimen after a total 
pancreatectomy. In contrast to FDG-PET, we also 
found low diffusion values in the main pancreatic duct 
and the distal common bile duct. Yamashita et al. 
found restricted perfusion in mucine-containing 
pancreatic cysts as compared to cysts of other origins at 
a b-value of 300 s/mm2 [24]. Thus, our findings 
indicate mucin or papillary tumor components filling 
the pancreatic duct system and the distal common bile 
duct. This is the first intraductal oncocytic papillary 
neoplasm case study which includes diffusion-
weighted imaging. Only one recent study evaluated 
diffusion-weighted imaging in IPMNs and showed no 
restricted diffusion, indicating its feasibility in 
differentiating these two entities [25]. 
All cystic tumor parts as well as the coexisting right-
sided kidney cysts showed higher intensity on 
diffusion-weighted imaging (b=150 s/mm2) as 
compared to the solid tumor nodules, with slightly less 
intensity on b=500 s/mm2, indicating a strong T2 shine-
through effect. Apparent diffusion coefficient maps 
confirmed the T2 shine-through effect by showing high 
values for all cystic parts and low values for the solid 
tumor part [26]. In a recent study, significant 
differences between the signal intensity ratios of 
pancreatic cystic lesions were found on images at a b 
factor of 1,000 s/mm2, making the differentiation of 
pancreatic cysts possible [27]. However, with a higher 
b factor (b =1,000 s/mm2), we obtained a very low 
signal-to-noise ratio causing anatomic distortion due to 
susceptibility effects which did not allow diagnostic 
image interpretation. This is a well-known problem for 
echo-planar sequences with higher b-values resulting in 
greater image distortion [28]. 
The clinical significance of preoperative differentiation 
of intraductal oncocytic papillary neoplasms from 
IPMNs can only be estimated at this point because the 
degree of malignant potential for intraductal oncocytic 
papillary neoplasms is still unclear due to the low 
number of cases reported. Standard surgical therapeutic 
intervention for both lesions is a pylorus-preserving 
pancreaticoduodenectomy, as was carried out in our 
case. However, the majority of the intraductal 
oncocytic papillary neoplasm cases reported in the 
literature were diagnosed as carcinomas including 
reports of invasive tumor growth and distant metastasis 
which changes the surgical procedure to extended 
pancreatectomy. In contrast, only one of these cases 
involved death from an intraductal oncocytic papillary 
neoplasm; good prognoses can be expected but short 
follow-up periods are indicated. 
 
CONCLUSION 
 
Intraductal oncocytic papillary neoplasms of the 
pancreas should be included in the differential 
diagnosis of cystic tumors with communication to the 
dilated pancreatic duct featuring intraductal tumor 
nodules. An intraductal oncocytic papillary neoplasm 
shows a high FDG uptake in PET and low diffusion 
values in diffusion-weighted imaging, including 
apparent diffusion coefficient maps which may be a 
valuable attribute in distinguishing these rare lesions 
from IPMNs. 
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